Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM: Quality of Life in Bone Metastasis Management
NCT02839291Active, not recruiting
- Sponsor
- CHU de Besançon
- Start
- Jun 2016
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of denosumab in bone metastasis, sponsored by CHU de Besançon. Primary endpoint: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Bone Metastases Module at 6 months. Started Jun 2016; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT02839291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839291.